Mass General Brigham Ventures

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham, focusing on advancing life science technologies developed within its research community. Established in 2008, the firm manages over $450 million in internal and external capital, investing in seed and early-stage companies across sectors such as therapeutics, digital health, diagnostics, devices, and tools. The firm leverages its position within the largest hospital system-based research enterprise in the U.S., including Massachusetts General Hospital and Brigham and Women's Hospital, to source and develop innovative solutions addressing unmet medical needs.

The firm's investment strategy emphasizes collaboration with strong co-investor syndicates to support portfolio companies through their entire financing lifecycle. This approach aims to attract capital and talent into the most challenging phases of company development, particularly the seed and Series A stages. By combining venture capital with Mass General Brigham's expertise in medical industry and its extensive network of scientific and business talent, the firm seeks to build transformative companies capable of delivering outstanding returns to investors while improving patient outcomes.

Since its inception, Mass General Brigham Ventures has invested over $200 million in 57 venture startups, with a portfolio that includes companies focused on central nervous system disorders, immunology, and gene and cell therapy. The firm has achieved 16 exits, with $140 million realized and publicly traded. Notable investments include Garuda Therapeutics, which raised a $155 million oversubscribed Series B round in February 2023, and other companies advancing innovative therapeutics and digital health solutions.